Skip to content

Study · Animal study (in vivo) · 2026

4 results

Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer.

Miller JS, Kane JF, Ward PA, Shawkey M, Watkins A, Johnson RW, Rhoades JA

Journal of bone oncology20 Feb 2026

PMID41798079 (opens in a new tab)PMCIDPMC12961290 (opens in a new tab)DOI10.1016/j.jbo.2026.100752 (opens in a new tab)PepBankPUB-41798079
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an intratibial cancer model, abaloparatide alone did not affect tumor burden in the tumor limb.

    In plain wordsIn an animal cancer model, abaloparatide alone did not change tumor burden in the tumor limb.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTumor burden with monotherapy
    Study

    n: not reported in source

    Intratibial cancer in bone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    •Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an intratibial cancer model, abaloparatide alone did not affect bone volume in the tumor limb.

    In plain wordsIn an animal cancer model, abaloparatide alone did not change bone volume in the tumor limb.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone volume with monotherapy
    Study

    n: not reported in source

    Intratibial cancer in bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    •Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.

Studies that did not test the peptide alone2

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 03AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In an intratibial cancer model, combined abaloparatide and paclitaxel reduced tumor burden.

    In plain wordsIn an animal cancer model, abaloparatide with paclitaxel reduced tumor burden.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseTumor burden with combination
    Study

    n: not reported in source

    Intratibial cancer in bone
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    •Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 04AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In an intratibial cancer model, combined abaloparatide and paclitaxel increased bone volume.

    In plain wordsIn an animal cancer model, abaloparatide with paclitaxel increased bone volume.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone volume with combination
    Study

    n: not reported in source

    Intratibial cancer in bone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    •Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.